Cargando…
Systematic review of phase‐I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research
BACKGROUND: Optimal Phase‐II design to evaluate new therapies in refractory/relapsed Ewing sarcomas (ES) remains imperfectly defined. OBJECTIVES: Recurrent/refractory ES phase‐I/II trials analysis to improve trials design. METHODS: Comprehensive review of therapeutic trials registered on five databa...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940237/ https://www.ncbi.nlm.nih.gov/pubmed/33452711 http://dx.doi.org/10.1002/cam4.3712 |